Antineoplastic Agents: Cytotoxic Agents: Mitotic Inhibitors
IHALA1 “Halaven injection” 0.5mg/ml; 2ml/vail
適應症：用於治療轉移性乳癌患者且曾接受過至少兩種針對轉移性乳癌之化學治療。先前之治療應包括anthracycline和taxane用於輔助性或轉移性治療。
Usual dose:
Liposarcoma, unresectable or metastatic, after a prior anthracycline-containing regimen: 1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8 of a 21-day cycle.
Metastatic breast cancer, after 2 or more chemotherapy regimens for metastatic disease: 1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8 of a 21-day cycle
Dose adjustment:
Renal impairment: moderate or severe (CrCl 15 to 49 mL/min): Reduce dose to 1.1 mg/m2 IV over 2 to 5 minutes on days 1 and 8 of a 21-day cycle.
Hepatic impairment:
Mild: reduce dose to 1.1 mg/m2 over 2 to 5 minutes on days 1 and 8 of a 21-day cycle
Moderate: Reduce dose to 0.7 mg/m2 IV over 2 to 5 minutes on days 1 and 8 of a 21-day cycle
Precaution: QT prolongation has been reported; monitoring recommended in high risk patients, severe neutropenia has been reported, with an increased risk in patients with elevated transaminase or bilirubin levels; monitoring recommended and therapy interruption with subsequent dosage adjustment may be necessary.
Adverse effect:
Common: alopecia, hypocalcemia, hypokalemia, constipation, nausea, anemia, neutropenia, peripheral neuropathy, fatigue.
Serious: prolonged QT interval, anemia, febrile neutropenia, neutropenia, thrombocytopenia, sepsis, neutropenic sepsis .
健保給付規定:
1.用於治療轉移性乳癌患者且先前曾接受過anthracycline和taxane兩種針對轉移性乳癌之化學治療輔助性治療。
- 需經事前審查核准後使用，每次申請療程以三個月為限，如發現病情惡化應停止使用。再申請應檢附前次治療結果評估資料。（103/12/1）